Please ensure Javascript is enabled for purposes of website accessibility

Pfizer and BioNTech Launch Coronavirus Vaccine Study for Pregnant Women

By Eric Volkman - Updated Feb 18, 2021 at 6:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The testing will also be extended to children.

With their BNT162b2 coronavirus vaccine now being distributed in major markets to inoculate the general public, Pfizer (PFE -1.83%) and BioNTech (BNTX -1.72%) have moved to test it on a new group of patients. The two companies announced on Thursday that they have started a global phase 2/3 clinical trial to test the efficacy of the vaccine in pregnant women age 18 and older.

For the placebo-controlled study, Pfizer and BioNTech aim to recruit around 4,000 healthy pregnant women, to be vaccinated between 24 to 34 weeks into their terms. As is standard with BNT162b2, each will receive two doses of the vaccine; these will be spaced 21 days apart. Mothers will be monitored, as will their offspring from birth until roughly six months of age.

Pregnant woman receiving an injection from a medical professional.

Image source: Getty Images.

"Now that we are seeing successful initial implementation of vaccine campaigns with BNT162b2 across the globe, it is time to take the next step and extend our clinical program to other vulnerable populations, such as pregnant women, to potentially protect both them and future generations," Pfizer and BioNTech quoted the latter's chief medical officer, Ozlem Tureci, as saying.

The two companies added that, in the coming months, they plan to begin additional clinical studies in children age 5 to 11. They will also launch testing on children under 5 later this year. At the moment, they are evaluating the vaccine's effect on those between the ages of 12 and 15, in a global phase 3 trial.

In the U.S., BNT162b2 is one of only two vaccines (along with Moderna's mRNA-1273) that have received Emergency Use Authorization from the Food and Drug Administration.

On Thursday, both Pfizer and BioNTech shares fell more steeply than the 0.4% decline of the S&P 500 index, with the former stock slumping nearly 1%, and the latter dropping 0.8%.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.40 (-1.83%) $0.94
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$137.71 (-3.21%) $-4.57
BioNTech SE Stock Quote
BioNTech SE
BNTX
$157.06 (-1.72%) $-2.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.